Reading ANNX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANNX free→Reading ANNX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANNX free→NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, while management's recent track record has been steady. The company was unprofitable over the past year, so its earnings quality can't be assessed, and risk is elevated. The sector backdrop is a headwind, which may impact performance compared with sector peers. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $4.52. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.93x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
3 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.30 → $-0.24 (+20.6% / 30d). 4 raised, 0 cut, 6 covering analysts.
0 upgrades, 0 downgrades / 30d. 90% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$259.
How much price usually moves either way.
On a bad day, this stock has moved -$710.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,506.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If healthcare sector growth speeds up, it may benefit Annexon. This could improve investor confidence.
Confirms:Healthcare sector revenue growth rises above 10% year over year.
Disproves:Healthcare sector revenue growth remains below 10% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ANNX yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
of this Current Report on Form 8-K, including Exhibit 99.1, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ANNX Annexon, Inc. | — | — | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 86 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 81 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 99 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Annexon aims to fund its operations and anticipated milestones into the second half of 2027 through focused investments.
Stated in 2 of last 2 quarters. Annexon has reiterated its expectation to fund operations into the second half of 2027. However, financials show persistent negative cash from operations, with -$46.8M in 2026-Q1 and -$45.9M in 2025-Q4, indicating limited progress towards self-sustaining operations.
“Annexon expects to fund operations and anticipated milestones into the second half of 2027.”
“Annexon continues to expect its cash to fund operating expenses into the fourth quarter of 2026.”
Annexon is focused on achieving milestones for its lead late-stage programs.
Newly stated in 2026-Q1. Annexon has highlighted its focus on achieving milestones for its lead late-stage programs. Despite this focus, the financials reveal ongoing operating losses, with net income at -$44.1M in 2026-Q1, suggesting limited progress in achieving financial sustainability through these programs.
“Focused investments in its lead late-stage programs are expected to fund anticipated milestones.”
Results of Operations and Financial Condition. On March 30, 2026, Annexon, Inc. (the “Company”) announced certain financial results for the fourth quarter and the year ended December 31, 2025. A copy of the Company’s press release, titled “Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones” is furnished pursuant to
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On February 12, 2026, Thomas G. Wiggans, Chairman of the Board of Directors (the “Board”) of Annexon, Inc. (the “Company”), notified the Company of his intent to retire as a member of the Board and therefore not stand for reelection at the Company’s 2026 annual meeting of stockholders (the “2026 Annual Meeting”). Accordingly, Mr. Wiggans’ term as a…
Entry into a Material Definitive Agreement. On November 12, 2025, Annexon, Inc. (the “ Company ’) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, TD Securities (USA) LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters listed therein (collectively, the “ Underwriters ”), to issue and sell 25,096,153 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”) at a p…
of this Current Report on Form 8-K, including Exhibit 99.1, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.